Gwenaella Rescourio

This inventor holds 18 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Amgen Inc., Vigil Neuroscience, Inc., Corsair Pharma, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gwenaella Rescourio. Retrieved from https://idiyas.com/inventor/gwenaella-rescourio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 6.3

ph-index = 3

Forward Citations = 109(Granted Patents)

Location History:

Sunnyvale, CA (US) (2014 - 2016)
San Mateo, CA (US) (2013 - 2017)
Cambridge, MA (US) (2020 - 2022)
Thousand Oaks, CA (US) (2023 - 2024)
South San Francisco, CA (US) (2024)

Company Filing History:

Vigil Neuroscience, Inc.

Theron Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Treprostinil Derivatives

Mcl-1 Protein Antagonists

7-Azoniabicyclo

Pyridine Sulfonamides

Pharmaceutical Uses

Triggering Receptor

Bioisostere

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428425 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-09-30),

2. 12365663 - Treprostinil derivative compounds and methods of using same (2025-07-22),

3. 12319691 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-06-03),

4. 12252489 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2025-03-18),

5. 11958822 - Treprostinil derivative compounds and methods of using same (2024-04-16),

6. 11912711 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-02-27),

7. 11884675 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2024-01-30),

8. 11718617 - Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use (2023-08-08),

9. 11608344 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use (2023-03-21),

10. 11274105 - Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists (2022-03-15),

11. 10668067 - Pyridine sulfonamides (2020-06-02),

12. 9845305 - Treprostinil derivative compounds and methods of using same (2017-12-19),

13. 9505737 - Treprostinil derivative compounds and methods of using same (2016-11-29),

14. 9371264 - Treprostinil derivative compounds and methods of using same (2016-06-21),

15. 9320731 - 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof (2016-04-26),

Title: Top Inventor in San Mateo

Introduction: Thierry Cruanes is a prominent inventor based in San Mateo, California. Notably, she is a woman who has made significant contributions to her field.

Latest Patents: Thierry has recently been awarded several patents that showcase her innovative ideas and technical expertise.

Career Highlights: Throughout her career, Thierry has achieved numerous milestones that highlight her dedication and impact in the industry.

Collaborations: She has worked with various organizations and individuals, fostering partnerships that enhance her work and broaden her influence.

Conclusion: Thierry Cruanes stands out as a leading inventor, inspiring others with her achievements and commitment to innovation.

Profile summary based on public USPTO records.